Category: ACN Newswire

IGG Inc 2025 Annual Financial Highlights and 2026 Business Update:- In 2025, the Group maintained stable operations, achieving revenue of HK$5.5 billion, representing a modest year-on-year decrease of 4%. Mid-generation titles “Doomsday: Last Survivors” and “Viking Rise” delivered steady revenue growth, generating approximately HK$1.14 billion and HK$720 million, respectively, representing year-on-year increases of 12% and 6%. The APP Business achieved revenue of HK$1.06 billion. “Lords Mobile”, IGG’s flagship title launched ten years ago, made a significant contribution of HK$2.17 billion in revenue.- The Group achieved net profit of nearly HK$590 million in 2025, representing a year-on-year increase of 1%. Net profit from the Group’s core business amounted to approximately HK$570 million, while profit from investments contributed approximately HK$20 million.- The Group has consistently prioritized returns to shareholders and increased dividend payout for the second half of 2025. The Board of Directors declared a second interim dividend of HK6.7 cents per ordinary share, and a special dividend of HK47.7 cents per ordinary share, totalling HK54.4 cents per ordinary share. The Group allocated approximately HK$890 million for share buy-backs and dividends in 2025, which corresponds to approximately 152% of annual profit.- Entering 2026, the mid-generation title “Doomsday: Last Survivors” continues its upward trajectory, achieving record monthly gross billings of HK$130 million starting from December last year, with strong performance expected to continue. New game “Fate War” has built solid momentum and is poised for further growth.HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) – IGG Inc (“IGG” or “the Group”, stock code: 799.HK), a leading global developer and operator of mobile games and applications, is pleased to announce the audited consolidated financial results of the Group for the year ended 31 December 2025.In 2025, the Group recorded a stable annual revenue of HK$5.5 billion. Despite a slight year-on-year fluctuation in revenue, the Group successfully maintained full-year profit at nearly HK$590 million (comprising approximately HK$570 million in net profit from the Group’s core business (non-IFRS measure) and approximately HK$20 million from investments) through refined management and business structure optimization, demonstrating strong profitability and risk resilience. Notably, mid-generation titles “Doomsday: Last Survivors” and “Viking Rise” maintained solid momentum and achieved new revenue highs in their third year of operation. In 2025, “Doomsday: Last Survivors” and “Viking Rise” contributed approximately HK$1.14 billion and HK$720 million, respectively, representing year-on-year increases of 12% and 6%. The APP Business generated revenue of HK$1.06 billion. Together, these three contributors accounted for 53% of the Group’s revenue in 2025, reflecting the continued success of its diversified growth strategy. In addition, “Lords Mobile”, IGG’s flagship title, reached its 10-year milestone and made a significant contribution of HK$2.17 billion in revenue. During the year, revenue from Asia, Europe and North America accounted for 41%, 36% and 19%, respectively, of the Group’s total revenue. As at 31 December 2025, the Group’s mobile games were available in 23 different languages worldwide, with approximately 1.6 billion users in total and nearly 17 million monthly active users (“MAU”) across more than 200 countries and regions.“Lords Mobile”, IGG’s blockbuster title, reached its 10-year milestone during the year. It is the Group’s first cross-platform, multi-language game that integrates strategy, role-playing, and real-time competitive gameplay. Lauded by Sensor Tower for its longevity, it is designed for a global audience. It has received widespread acclaim from gamers, and consistently generates stable revenue for the Group. During the year, “Lords Mobile” launched a series of IP collaborations, including the film “Pacific Rim”, the game “Angry Birds”, and, more recently, original fantasy characters created by “tokidoki” co-founder and artist Simone Legno, injecting renewed vitality and immersive gameplay. As the bedrock of the Group’s operations, “Lords Mobile” delivered revenue of HK$2.17 billion, consistently contributing stable cash flow to the Group.After over three years of cultivation, the Group’s two growth drivers, “Doomsday: Last Survivors” and “Viking Rise” delivered solid results with revenue growing 12% and 6% year-on-year respectively, against market trends. Their lifecycles have also surpassed industry norms. During 2025, “Doomsday: Last Survivors” enhanced gameplay through the launch of new battlefield and squad equipment features. The game also collaborated with the renowned manga IP “Attack on Titan” which was well-received by its nearly 100 million users. In 2025, the game contributed revenue of HK$1.14 billion. The title continued its upward trajectory, with monthly gross billings reaching record highs starting from December at HK$130 million, demonstrating strong user engagement and future growth.“Viking Rise”, the Group’s other mid-generation Viking-themed title, also contributed solid results. During 2025, the game introduced hybrid-casual combat gameplay, collaborated with renowned IP “How to Train Your Dragon (Live Action)”, and rolled out offline competitions to strengthen engagement and social interaction among players. As of 31 December 2025, the game had 67 million registered users and revenue of HK$720 million, representing a 6% year-on-year increase.“Fate War”, a new strategy game released in 2025, established a new growth trajectory. Upon launch, the game was prominently featured on Apple’s App Store and Google Play Store worldwide because of its unique blend of simulation and strategy gameplay. This recognition validates the title’s exceptional quality and builds strong momentum for future revenue growth. As of 31 December 2025, the game achieved monthly gross billing of HK$30 million, with approximately 4.7 million registered users and 1.2 million monthly active users.Leveraging its global operational expertise and a base of more than 1 billion users, the Group established a second growth curve through its APP Business. Contributing 19% of the Group’s revenue, this business validates the Group’s user acquisition and monetization capabilities beyond gaming, delivering genuine business diversification. In 2025, it generated revenue of HK$1.06 billion and net profit of over HK$100 million. During the year, the APP Business had more than 67 million monthly active users, representing a year-on-year increase of 8%.The Group consistently prioritizes shareholder returns. In light of the Group’s solid financial position and its sustained long-term development, the Board of Directors has resolved to materially increase shareholder distributions, declaring a total dividend (including a second interim dividend and a special dividend) of HK54.4 cents per ordinary share. Aggregate shareholder returns for 2025 (encompassing dividends and share buybacks) totalled HK$890 million, constituting 152% of annual profit. This elevated distribution ratio serves as a clear testament to management's confidence in the Company's cash generation capacity and future growth potential. Looking ahead to 2026, the Group has established a solid foundation for growth: the core gaming portfolio continues to serve as a strong growth driver, with “Doomsday: Last Survivors” expected to maintain its strong performance trajectory; “Fate War”, the Group’s new title, is entering a harvest period and will progressively generate enhanced revenue contributions; and the APP Business represents a well-defined secondary growth curve. The Group will continue to deepen its global operational excellence and advance the coordinated development of its diversified product matrix, with the objective of generating enduring, sustainable value for shareholders.[1] APP Business: development and operations of the Group’s mobile applications.[2] Net profit for core business (non-IFRS measure): net profit excluding gain/loss on investments. Gain/loss on investments including: (1) fair value change and gain/loss on disposal of other financial assets or liabilities and assets held for sale, and dividend income; and (2) share of results of associates and joint ventures, impairment loss on interest in associates and joint ventures and net gain/loss on disposal and deemed disposal of associates and joint ventures.[3] Monthly gross billing as of December 31, 2025 and January 31, 2026[4] “Lords Mobile” was awarded “Best Evergreen Strategy Game” at the Sensor Tower APAC Awards 2025.[5] User data as of December 31, 2025[6] Monthly gross billing for December 2025About IGG IncEstablished in 2006, IGG Inc is a leading global developer and operator of mobile games and applications, with headquarters in Singapore and local offices in the United States, China, Canada, Japan, South Korea, Thailand, the Philippines, Indonesia, Brazil, Türkiye, Italy and Spain. IGG offers multi-language and multifarious games and mobile applications to users around the world. The Group has established long-term partnerships with over 100 business partners, including global platforms, advertising channels, and vendors such as Apple, Google and Meta. IGG’s most popular games include “Lords Mobile”, “Doomsday: Last Survivors”, “Viking Rise”, “Time Princess”, “Fate War”, along with a diverse range of mobile applications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IGG集團2025年度業績摘要及2026年最新業務情況：- 2025年，集團運營穩健，實現重大收入55億港元，同比微減4%。中生代遊戲《Doomsday: Last Survivors》和《Viking Rise》穩步攀升，分別貢獻約11.4億港元和7.2億港元，同比增長12%與6%。APP業務收入創造10.6億港元。經典產品《王國紀元》上線邁進第十年里程碑，穩健長青，貢獻收入21.7億港元。- 集團全年利潤近5.9億港元，同比增長1%。其中，主營業務利潤貢獻約5.7億港元；投資業務利潤約0.2億港元。- 集團一貫重視回饋股東，本期加大派息，董事會宣派2025年度第二次中期股息每股6.7港仙，以及特別股息每股47.7港仙，合計每股54.4港仙。2025年度，集團累計回購及股息金額共約8.9億港元，佔全年利潤的152%。- 展望2026年，中生代遊戲《Doomsday: Last Survivors》厚積薄發， 去年12月起連續突破歷史峰值，月流水站上1.3億港元新台階，強勁增長勢頭有望持續。新銳遊戲《Fate War》攢足動能，蓄勢待發。香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 全球領先的手機遊戲與移動應用開發商及營運商IGG Inc （「IGG」，或「集團」，股份代號：799.HK）欣然宣佈集團截至2025年12月31日止之經審計年度綜合業績。2025年，集團總收入穩健維持在55億港元的高位。儘管收入同比略有波動，但集團通過精細化管理與業務結構優化，成功將全年利潤穩定在近5.9億港元（主營業務利潤（非IFRS指標）貢獻約5.7億港元；投資業務利潤約0.2億港元），彰顯了優異的盈利能力和抗風險韌性。令人鼓舞的是，中生代遊戲《Doomsday: Last Survivors》與《Viking Rise》厚積薄發，推廣三年多，收入持續新高。2025年，《Doomsday: Last Survivors》與《Viking Rise》分別貢獻約11.4億港元和7.2億港元，同比增長12%與6%。此外，APP業務收入不遑多讓，高達10.6億港元，三大項目收入佔比53%，推動集團多元發展。集團經典遊戲《王國紀元》上線邁進第十年里程碑，穩健長青，為集團貢獻重大收入21.7億港元。收入區域分佈方面，來自亞洲、歐洲及北美市場的收入分別佔集團收入的41%、36%及19%。截至2025年12月31日，本集團以23種不同語言版本向全球發行手遊產品，擁有來自於全球200多個國家和地區的遊戲總用戶數約16億，遊戲月活躍用戶近1,700萬。本集團金牌手遊《王國紀元》迎來上線十週年里程碑，歷久彌新，獲Sensor Tower評選為「常青遊戲」。作為集團首款匯集跨平台、多語種，融合策略、角色扮演與實時競技體驗的經典遊戲，持續獲得全球玩家青睞，並貢獻穩健收益。年內，《王國紀元》推出一系列IP聯動，包括電影《環太平洋》系列、遊戲《Angry Birds》，以及近期「tokidoki」聯合創始人兼藝術家Simone Legno帶來的奇幻原創角色，為產品灌注新活力。作為集團業務的壓艙石，《王國紀元》遊戲實現21.7億港元營收，持續為集團貢獻穩定現金流。集團兩大成長引擎《Doomsday: Last Survivors》與《Viking Rise》推廣三年多，厚積薄發，年內收入分別逆勢增長12%與6%，其生命週期更超越行業預期。年內，《Doomsday: Last Survivors》推出全新公會戰玩法與部隊裝備功能，近期更與超人氣動漫「進擊的巨人」攜手展開全球IP聯動，廣獲億萬玩家喜愛。2025年，遊戲貢獻11.4億港元營收，月流水更自12月起連續突破歷史峰值，站上1.3億港元的新台階，證實了其強大的用戶黏性與未來成長空間。另一款中生代核心遊戲《Viking Rise》，以維京題材貢獻穩健業績。2025年，遊戲引入輕量化對戰玩法、攜手知名真人電影「馴龍高手」打造重磅IP聯動，並舉辦線下競技賽事，提升玩家策略體驗與社交粘性。截至2025年12月31日，遊戲註冊玩家6,700萬，貢獻7.2億港元營收，收入同比增長6%。新遊戲方面，集團旗下重磅策略新作《Fate War》於2025年隆重推出，成功打開了新的增長曲線。遊戲創新融合了「模擬經營+策略競技」雙核玩法，甫一上線，即獲得蘋果與谷歌雙平台在全球市場的重點推薦，印證了遊戲的卓越品質，為未來收入增長儲備了重要動能。截至2025年12月31日，遊戲月流水突破3,000萬港元，註冊用戶約470萬，月活躍用戶達120萬。依託全球化買量方面的領先優勢，及積累的十多億用戶畫像，集團成功孵化了第二增長曲線—APP業務。該業務不僅貢獻集團19%營收，更證明了集團在非遊戲領域的用戶獲取與變現能力，實現了真正的業務多元化。2025年，APP業務為集團創造10.6億港元收入，並貢獻逾億港元的可觀利潤。年內，APP業務突破6,700多萬月活躍用戶，較去年增長8%。集團始終將股東回報置於核心位置。基於健康的財務狀況及對長期發展的信心，董事會決議大幅提升股東回饋，宣派2025年度第二次中期股息及特別股息合計每股54.4港仙。2025年全年股東回報（包括股息與股份回購）高達8.9億港元，相當於全年利潤的152%。這一高比例回報政策，清晰地傳達了管理層對公司現金流生成能力及未來增長前景的信心。展望2026年，IGG已奠定紮實的增長基礎：核心遊戲增長引擎動力十足，《Doomsday: Last Survivors》的強勁勢頭有望持續；新遊戲《Fate War》進入收穫期，將逐步貢獻更大收入；APP業務第二增曲線增長明確。集團將繼續深化全球運營優勢，推動多元化產品矩陣協同發展，旨在為股東創造長期而可持續的價值。[1] 移動應用的開發與運營（簡稱「APP業務」）[2] 主營業務利潤（非IFRS指標）：指扣除投資相關損益後的集團淨利潤。投資相關損益：包括（1）其他金融資產或負債及持有待售資產之公允價值變動及其處置損益，以及股息收入，（2）應佔聯營公司及合營企業的業績、聯營公司及合營企業的權益的減值損失及處置和視同處置的淨損益。[3] 單月流水數據分別截至2025年12月31日與2026年1月31日[4] 《王國紀元》 榮獲Sensor Tower頒發的《APAC Awards 2025 – 最佳常青策略遊戲》[5] 註冊用戶數據截至2025年12月31日[6] 2025年12月流水數據關於IGG IncIGG集團創立於2006年，是一家全球領先的手機遊戲及移動應用開發商及營運商，總部設在新加坡，於美國、中國、加拿大、日本、韓國、泰國、菲律賓、印尼、巴西、土耳其、意大利及西班牙等地區設有分支機構。IGG爲世界各地的用戶提供多語言、多類型的精品遊戲及移動應用。除Apple、Google和Meta等主要合作夥伴外，集團已與全球逾百家國際平台、廣告商及供應商夥伴佈建長期合作關係。IGG最受歡迎的產品包括《王國紀元》、《Doomsday: Last Survivors》、《Viking Rise》、《時光公主》、《Fate War》等遊戲，以及多元化移動應用。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 收入增長41%至62.30億港元，創歷史新高- 稅後利潤躍升287%至13.45億港元- 總資産上升18%至1,535億港元- 金融産品業務規模上升18%至474億港元- ROE顯著提升6.4個百分點至8.7%- 建議派發末期股息每股2港仙，全年派息7港仙，派息比率50%，每股股息增長119%業務亮點：- 投行業務創歷史最佳表現，收入大幅增長133%- 港股IPO保薦項目7個，配售項目34個，配售按數量市場排名第一- 債券發行項目294個，發行規模增長34%- OTC産品交易量爆發式增長，成爲佣金收入主力來源之一- 港交所場內衍生品累計成交中資券商排名第一- 資産管理業務規模增長49%，收入大幅增長1.2倍- 中資離岸ESG債券主承銷金額中資券商排名第一- 連續10年獲穆迪「Baa2」、標普「BBB+」長期發行人評級，展望「穩定」- MSCI ESG 獲提升至最高AAA評級， 連續第三年營運層面碳中和香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」、「集團」或「公司」，股份代號：1788.HK）秉持穩健務實的經營理念，堅守風險底綫，聚焦核心主業，推動各業務實現全面高質量增長，經營成果豐碩。年內，集團收入創歷史新高，同比大幅上升41%至62.30億港元，普通股股東應佔溢利同比大幅躍升287%至13.45億港元，盈利規模實現跨越式提升。董事會建議宣派截至2025年12月31日年度之末期股息每股0.02港元，連同已派發的中期股息每股0.05港元，全年股息合共每股0.07港元，派息比率50%，每股股息增長119%。厚積薄發，財富管理2.0拉開帷幕2025年，集團全面推進財富管理2.0戰略落地，堅持「客戶需求爲核心、定制化服務爲特色、數字化能力爲支撑」的發展方向，完成「平台+産品」綜合性升級。年內，OTC産品交易增長迅猛，成爲佣金收入主力來源之一，其中結構性票據、OTC期權佣金均同比躍升超過100%，產品交易量、客戶參與人數較2024年分別增長超50%，成為集團財富管理業務高質量發展的核心支柱。同時，集團深化科技金融與普惠金融佈局，完成交易平台數智化升級，「君弘全球通」活躍用戶大幅增長，有效帶動客戶託管資產規模提升。2025年，集團資産管理業務實現規模、收入雙增長，資産管理規模同比增長49%，收益躍升1.2倍。投資級債券基金Class I年化回報率達8.96%，位列中資同業前茅；美元貨幣基金Class A2年化回報率約4.38%，穩居同類產品第一梯隊。企業融資創佳績，規模效益創新高依託與母公司國泰海通證券的協同優勢，2025年，集團股權融資業務繼續聚焦新科技、機器人、人工智能等前沿賽道，創歷史最好表現，全年共完成七單IPO保薦項目，數量居中資投行前列，集資總額超過160億港元，遞交上市申請共25個項目（不含保密遞交的申請）。其中，本集團獨家保薦的上海劍橋科技（6166.HK）創下A股與港股通信設備行業史上最大規模IPO記錄；臥安機器人（6600.HK）爲智慧家庭機器人第一股；集團聯席保薦的禾賽科技（2525.HK）為2022年以來募資規模最大的中概股回歸項目。此外，年內，集團完成34個二級市場配售項目，按項目數量計排名市場第一。2025年，集團共參與294筆境外債券的發行項目，發行總規模約5,221億港元，同比增長34%。根據DMI債券平台數據顯示，集團離岸債一級承銷規模在中資券商中排名第三，中資離岸債主承銷規模位列中資券商第二。集團服務客戶涵蓋大型國有企業、金融機構、地方政府等各類發債主體，業務實力穩居行業領先地位。機構業務穩定發展，產品服務領跑市場集團持續為機構投資者提供跨境、跨資產、跨市場一站式服務，依託滬港通、深港通等互聯互通機遇，深化與母公司協同，整合境內外資源優勢，提升產品設計與交易能力。截至2025年年底，代客持有金融產品規模同比增長17.7%至474億港元，淨收益平穩提升。在港股衍生品領域，集團場內衍生品交易量同比顯著增長，穩居中資券商領先地位。深耕綠色金融，推進低碳運營本集團堅守「金融報國，金融爲民，金融向善」信念，將ESG理念融入日常業務營運及管理中。在綠色金融服務方面，集團持續深耕ESG債券市場，年內完成86筆ESG債券發行，融資規模約達2,044億港元，同比增加25%，於DMI中資離岸ESG債券主承銷金額排名中位列中資券商第一名，彰顯了在綠色金融領域的領先地位。低碳運營發展方面，公司在堅持踐行節能减排的基礎上，通過認購核證碳標準林業項目碳匯資産成功抵銷2024年度範圍1及範圍2溫室氣體排放，連續第三年實現營運層面碳中和，展現了本公司在應對氣候變化方面的堅定承諾和卓越表現。本公司MSCI ESG、萬得ESG和商道融綠ESG的評級均領先同業，其中MSCI ESG評級達最高AAA級，標普全球ESG評分領先全球81%同業，彰顯可持續發展核心競爭力。展望2026年，國泰君安國際將堅持穩中求進總基調，主動應對市場變化，聚焦核心業務提質增效，深化客戶中心理念，構建覆蓋機構、企業及個人客戶的全週期綜合金融服務體系，持續提供精準、多元、高效的一站式金融解決方案，推動各項業務高品質發展再上新台階。完整版公告請參閱：https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0325/2026032500354_c.pdf聲明本文稿不構成購買或認購任何證券或金融工具或提供任何投資建議的邀請或要約，幷且其任何部分不構成或依賴與任何合同、承諾或與此相關的投資决策，本文稿亦不構成有關公司之證券或金融工具的建議。本文稿包含有關集團財務狀况、經營業績的若干前瞻性陳述，及集團管理層的若干計劃及目標。這些前瞻性陳述涉及已知和未知的風險、不確定性和其他因素，可能導致實際業績或業績與前瞻性陳述所表達或暗示的任何未來業績或業績截然不同。這些前瞻性陳述是基於集團現在和將來的策略以及集團將來經營的政治和經濟環境的假設。不應將這些前瞻性陳述放在這些前瞻性陳述之上，反映集團管理層截至本次發布的觀點。不能保證未來的結果或事件與任何這樣的前瞻性陳述一致。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）, 是中國證券公司國際化的先行者和引領者，公司是首家通過IPO於香港交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，並在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 全民養生潮爆發。不只是中老年"銀發群體"，就連Z世代都不"浪"了，開始學習中醫知識、吃食補藥膳、打太極拳......在某視頻平臺，《八段錦》的播放量高達7880萬。在某社交平臺，"健康養生"話題的瀏覽量累計超過百億次。政策持續支持，近期又加了把"火"。十五五規劃綱要明確：全面實施AI+。加快建設健康中國，推進中醫傳承創新。需求和政策的雙重驅動下，中醫醫療服務行業的確定性愈加凸顯。據弗若斯特沙利文測算，到2029年，市場規模將達到1.62萬億元，未來幾年的CAGR約9.9%。[1]同時，一家萬億風口上的"龍頭"——同仁堂醫養，正備受青睞。一方面，它積極擁抱AI，以優質普惠的中醫醫養服務+成熟供應鏈，收獲了全國超過76萬會員用戶的信任。另一方面，作為"AI+中醫醫療服務"龍頭，它是稀缺的"壓艙石"資產，不僅填補了港股空白，也讓全球投資者能夠分享中國人口轉型和民族醫藥複興的紅利。機構投資者嗅覺敏銳，已搶先布局。據悉，航空港科技資本、Aurora SF，已經與同仁堂醫養簽訂了基石投資協議。值得注意的是，他們已承諾，上市後7個月內不會賣出。這一禁售期限，比港交所的規定（最低6個月）更長。顯然，這是看好同仁堂醫養的中長期價值。而在當下的港股市場，信心比黃金更重要。1、全產業鏈協同，夯出百年護城河十年前養生，"西式產品"風靡全球。如今，望聞問切、藥膳膏方、針灸推拿等"中式醫養方案"，正越來越火。甚至連老外也爭相加入，直呼"上頭，舒服"。風向的轉變，源於中醫醫養的獨特優勢：治未病，副作用較小，強調人體內部系統的平衡與和諧，更注重養生保健和長期健康管理。這，正好適配當前的養生需求。老齡化趨勢疊加快節奏生活，我國慢性病患病率不斷上升。據國家衛健委統計，有75.8%的老年人至少被1種慢性病困擾。[2]從高層到行業，已經形成共識：中醫醫養服務，有助於提升國民健康質量。但，問題出在了供給端。經驗豐富的中醫醫師極度稀缺，且大多執業於三甲醫院。即便患者搶到了專家號，診療結束即服務終止，後續很難再互動，更遑論持續的健康管理。該如何破局？同仁堂醫養敢於啃"硬骨頭"，給出了解題思路：全產業鏈協同。品牌端，同仁堂擁有350餘年曆史，家喻戶曉，自帶"信任基石"。同時，它始終錨定醫療服務的本質，潛心練功，鍛造出了嚴肅專業、高質量的醫療服務能力。截至去年9月末，平臺擁有2745名中醫執業醫師。其中，820名是主任醫師或副主任醫師，有30名執業醫師擁有國家級榮譽稱號。在此基礎上，同仁堂醫養進一步打通服務堵點，線上線下融合協同，已建立起全面、強大的分級診療網絡。在線上，數智化診療平臺突破時空限制，"老中醫"7×24小時極速響應，使優質的中醫醫養服務更加普惠。在線下，基層連鎖機構覆蓋社區場景，提供及時、貼心、溫暖的醫療需求，例如開展社區義診，為老人提供家庭醫生服務等。連鎖化的中醫院，有傳承，又有創新。它擁有先進的醫學檢查設備和領先的優勢專科能力，聚焦精細化醫學檢查和系統性診療服務，與互聯網醫院、基層機構，互為補充，大幅優化了資源配置。但，一家極致的公司，還不止於此。同仁堂醫養希望"把簡單留給用戶"，它背靠同仁堂集團，自帶中醫藥和供應鏈基因，"炮制雖繁必不敢省人工，品味雖貴必不敢減物力"。當診療完成後，它能直接提供優質可靠的藥品、藥膳、慢病調理膏方。至此，中醫醫養-醫藥供應鏈，形成了閉環服務生態。患者無需折騰，就能享受到優質、高效的醫療健康服務。用戶紛紛投出"信任票"。2025年前9個月，同仁堂醫養的推廣費占總營收比重僅0.1%。但同時期，總就診人次達到250萬人次，同比增長21.6%。會員人數方面，2022年-2024年CAGR達到30.2%，2025年前九個月增長至76.66萬。據弗若斯特沙利文調研數據，按2024年總門診人次及住院人次計，同仁堂醫養是中國非公立中醫院醫療服務行業中最大的中醫院集團，妥妥的行業龍頭。這，正是市場給予"新質供給"的掌聲和回報。2、高質量增長，強勁穩健的基本面當前，同仁堂醫養正處於港股招股階段，已引入2家基石投資者，散戶投資者也正積極踴躍申購。投資的底層邏輯，是強勁穩健的基本面。IPO招股書顯示，2022年-2024年，同仁堂醫養營業收入分別為9.11億元、11.53億元、11.75億元，持續穩健增長。2025年前9個月，營收8.58億元，保持增長勢頭。同時，其營收結構顯著優化，銷售健康產品及其他產品的占比達到13.6%，驗證了全產業鏈協同的邏輯。從地區來看，北京、浙江以外地區的營收規模增長了約17%，營收占比提升了2個百分點，意味著，業務擴張已見成效。利潤方面，同仁堂醫養於2023年扭虧後，一直保持著盈利狀態。2025年前9個月，得益於標准化運營+數智化轉型，其經營質效進一步提升，費用率優化至13.6%，毛利率18.2%。以長期視角看，這樣的高質量增長，才剛剛開始。招股書顯示，2024年，同仁堂醫養的市場份額為1.7%，整合空間巨大。未來，中醫醫療服務賽道將進入高景氣周期，規模萬億級。作為行業龍頭，同仁堂醫養已經構築起堅實的"護城河優勢"，且用戶信任、高粘性。另外，它擁有健康的現金流，此次IPO後，"資金彈藥"將更加充裕，能夠支撐業務擴張。可以預見，強者恒強，它有望吃下更多的"蛋糕紅利"。3、乘AI東風，開辟醫養"新航線"AI重塑醫療健康，數千年的中醫智慧正與新技術碰撞融合，煥發新生。中國工程院院士張伯禮認為，AI賦能，可以讓中醫更快地進步，飛得更高、飛得更遠。這是曆史性的機遇，也是每一家公司的必答題。同仁堂集團精准洞悉趨勢，積極擁抱AI浪潮。去年，其"牽手"小米公司，共同推出了AI智能體"同仁堂養生館"，它是一個AI中醫藥健康管家，能提供"健康問詢-分析-個性化建議"全流程服務。研發端，在北京市經濟和信息化局的支持下，其已落地AI新藥開發平臺建設項目，將構建十萬級方劑數據庫，驅動"經驗主義"進化至"數據主義"。同時，生產制造端也在"智變"。據悉，同仁堂集團旗下的"中醫藥全生命周期數智管控智能工廠"，已構建起13個AI應用場景，關鍵生產環節已全面完成智能化改造，實現了"全鏈智能"。作為大健康生態的"終端"，同仁堂醫養是"數智化排頭兵"，也正加速推進中醫醫療服務的數智化轉型。本次募資中，將有約5%的資金用於智慧醫療、數字化和智慧化改造。這將為其帶來更多的想象力。例如，AI將"解放"醫生，重構生產力，將使優質中醫醫養服務更加普惠、效率更高。當越來越多用戶湧入，不只會帶來業績的飛躍，還會產生更多數據反饋，驅動上遊中醫藥產品的創新研發。另外，AI還將助力管理服務業務，加速"同仁堂標准"的輸出。未來，同仁堂醫養可能不只是一家To C的醫療服務公司，還有望進階成為一家To H（醫療機構）的技術輸出公司。乘AI東風，一家百年老字號，正開辟"新航線"。同仁堂醫養，戰亂世界的"壓艙石"，已經站上了價值遷躍的新起點。參考資料：[1]同仁堂醫養IPO招股書[2]慢性病成老年健康頭號殺手，如何做好慢病管理？-中國新聞網轉載自懂財帝 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA-ASI）在上週《航空週刊》第 21 屆年度「計畫卓越獎」頒獎典禮中，榮獲兩項大獎。GA-ASI的英國「守護者」計畫榮獲「特別專案獎」，而其日本COCO（公司擁有、公司營運）計畫則在「原始設備製造商系統維運」類別中勝出。「我們很高興這兩個重要的 MQ-9B 國際計畫獲得《航空週刊》的肯定，」GA-ASI 執行長林登·布魯表示。「我們很幸運擁有這樣一支卓越的員工團隊，他們對客戶的奉獻精神與承諾實在令人讚嘆。」MQ-9B 是 GA-ASI 最先進的遙控飛行器（RPA）系統，包含 SkyGuardian® 與 SeaGuardian® 型號，以及英國的 Protector RG Mk1。2025年，GA-ASI 為英國皇家空軍（RAF）的「守護者」RG Mk1 無人機取得了首張軍用型號證書（MTC），該機通過了嚴格的適航評估，並驗證了其在無地理限制情況下的安全運作能力。英國「守護者」MTC的全球影響力備受認可，因為這是一項獨特的成就，使無人機系統能夠從英國皇家空軍國內基地出發，在民用空域進行常規運作，大幅提升其作戰靈活性，並減少對隔離飛行區或海外部署的依賴。但更重要的是，這為未來尋求全面整合至受管制空域的無人系統提供了概念驗證，並為全球盟軍及北約部隊樹立了先例。在日本，MQ-9B「海衛士」（SeaGuardian）COCO計畫成效卓著，原先租賃給日本的機體現已轉為銷售，且已追加訂購更多MQ-9B。日本利用「海衛士」在海上領域的任何地點——無論晝夜——提供即時戰況感知。它也是同級別中首款能夠在海面以上及以下進行即時搜索與巡邏的無人機。關於 GA-ASI通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）是全球首屈一指的無人機系統（UAS）製造商。「捕食者®」（Predator®）系列無人機系統累積飛行時數已超過 900 萬小時，服役時間逾 30 年，產品陣容包含 MQ-9A「死神®」（Reaper®）、MQ-1C「灰鷹®」（Gray Eagle®）、MQ-20「復仇者®」（Avenger®）、MQ-9B「天衛®」（SkyGuardian®）/「海衛®」（SeaGuardian®）、XQ-67A 及 YFQ-42A。本公司致力於提供長航時、多任務解決方案，以實現持續的戰場態勢感知與快速打擊能力。欲了解更多資訊，請造訪 www.ga-asi.com 。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 及 SkyGuardian 均為通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）於美國及／或其他國家註冊的商標。GA-ASI 媒體關係通用原子航空系統公司 ASI-MediaRelations@ga-asi.com (858) 524-8101消息來源：通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) was named the winner of two awards during Aviation Week's 21st annual Program Excellence Awards last week. GA-ASI's United Kingdom (UK) Protector Program was given the Special Projects Award, while its Japan COCO (Company-Owned, Company-Operated) Program won in the category of OEM System Sustainment."We're excited that these two important MQ-9B international programs have been recognized by Aviation Week," said GA-ASI CEO Linden Blue. "We're fortunate to have an incredible team of employees whose dedication and commitment to our customers is truly remarkable."MQ-9B is GA-ASI's most advanced Remotely Piloted Aircraft (RPA) system and includes the SkyGuardian® and SeaGuardian® models, as well as the UK's Protector RG Mk1.In 2025, GA-ASI achieved the first-ever Military Type Certificate (MTC) for the Royal Air Force's (RAF) Protector RG Mk1, passing a rigorous airworthiness assessment and verifying its safe operation without geographic restrictions. The global impact of the UK Protector MTC was recognized because it's a singular achievement that enables routine UAS operations in civil airspace from domestic RAF bases, drastically expanding its operational flexibility and reducing reliance on segregated ranges or overseas deployments. But more importantly, it serves as a proof of concept for future unmanned systems seeking full integration into regulated airspace and sets a precedent for allied and NATO forces worldwide.In Japan, the MQ-9B SeaGuardian COCO Program has proven so successful that the aircraft that had been leased to Japan have now been converted to sales, with additional MQ-9Bs now on order. SeaGuardian has been used by Japan to deliver real-time situational awareness anywhere in the maritime domain - day or night. It is also the first RPA in its class to enable real-time search and patrol above and below the ocean's surface.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, MQ-9B SkyGuardian®/SeaGuardian®, XQ-67A, and YFQ-42A. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Reno, Nevada--(ACN Newswire via SeaPRwire.com - March 24, 2026) - Scandium Mining Corp. (TSXV: SCY) (OTC PINK: SCYYF) ("Scandium International" or the "Company"), a leader in the advancement of critical mineral resources, is pleased to announce the release of its updated investor presentation, now available to investors and stakeholders. The new presentation can be accessed here: Investor PresentationThe new investor presentation provides updated information on the Nyngan project in New South Wales, Australia, which is now fully shovel-ready. This project is one of only two primary scandium deposits at this advanced stage in the western world, positioning the company at the forefront of the emerging scandium market.Scandium is an essential element in high-performance applications, including aerospace, defense, and clean power generation. Its unique properties-such as exceptional strength-to-weight ratio and improved corrosion resistance when alloyed with aluminum-make it indispensable for the next generation of lightweight, durable materials. As demand grows for advanced technologies and sustainable solutions, scandium's role is increasingly being recognized by innovative manufacturers and governments alike."We're excited to share this comprehensive update on our progress," said Peter Evensen, CEO of Scandium International. "With our mining license now valid over the entire resource, the project is shovel-ready and we are uniquely positioned to supply scandium at scale to industries that are shaping the future."To view the latest presentation and learn more about Scandium Mining's plans, visit: Scandium International Mining CorporationAbout Scandium MiningScandium Mining is dedicated to unlocking the potential of scandium for high-impact industries worldwide. With its shovel-ready primary scandium deposit, the company is committed to responsible development and long-term value creation.For inquiries to Scandium International Mining Corp, please contact: Peter Evensen, President and CEOTel: (775) 355-9500Harry de Jonge (Controller)Tel: (702) 703-0178Email: info@scandiummining.comCautionary Note Regarding Forward-Looking InformationThis news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289611 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 國際指數評級機構明晟 MSCI日前公佈了年度 ESG（環境、社會及企業管治） 評級報告，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK））評級從「A」級躍升至最高「AAA」級。公司在負責任投資、可持續融資業務、人力資本發展、數據安全及企業行為等領域表現尤為突出，處於全球同業領先水準。這一重要突破標誌著公司在可持續發展領域的持續努力與卓越表現獲得國際權威機構的高度認可。根據MSCI ESG評級的最新評估，國泰君安國際在多個關鍵議題上表現優異，成為本次評級上調的主要驅動因素：在負責任投資方面，得益於可持續發展指標的優化調整，公司得分顯著提升。公司始終致力於可持續發展，將負責任的投資理念全面融入投資組合管理，在投資流程中系統性地納入ESG因素，以此在傳統財務分析基礎上，進一步增強對潛在投資的ESG表現評估，從而推動被投資方的綠色轉型。在可持續融資業務方面，國泰君安國際在投資銀行業務中積極開展可持續發展盡職調查，並通過為企業客戶承銷及發行綠色債券，持續推動綠色金融發展，降低與業務相關的環境風險，展現了其在綠色投融資領域的責任擔當與專業能力。在人力資本發展方面，由於績效評估方法論的改進以及公司實踐的持續完善，得分亦實現增長。公司秉持「人才是第一資源」的經營理念，並奉行「以人為本、協同協作」的原則，視員工為本集團最有價值的資產。通過提升薪酬待遇、提供員工福利、創造成長機會，持續加強人才招募和留任策略，進一步鞏固公司作為優選雇主的地位，推動長期可持續發展。在數據安全領域，MSCI報告指出，國泰君安國際主要運營於香港這一隱私保護法規較為嚴格的地區，公司在數據安全實踐方面保持行業領先，通過制定覆蓋全集團的隱私政策，並引入外部獨立IT安全審計，公司有效構築了網路安全風險防線。國泰君安國際此次MSCI ESG評級躍升至AAA級，充分體現了公司在環境、社會及管治方面的長期投入與系統化建設成果。作為國泰海通集團的重要國際業務平台，公司將繼續秉持可持續發展理念，深化ESG治理實踐，積極履行社會責任，為股東、客戶及社會創造長期可持續價值。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港為業務基地，並在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，為客戶境外資產配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）為中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the Year, the Group’s revenue amounted to approximately HK$2,424.6 million, representing a decrease of approximately 6.9% as compared to the same period last year. Profit for the Year amounted to approximately HK$97.1 million, representing an increase of approximately 72.0% as compared to the same period last year. The Board recommends the payment of a final dividend for the Year at HK7.0 cents per share.Business Overview and ProspectsDuring the Year, revenue from cleaning services as the Group’s core business amounted to approximately HK$1,896.5 million, accounting for approximately 78.2% of the Group’s total revenue. The Group’s cleaning services cover various scenarios, including for Government streets, markets, police stations, fire stations, leisure venues, hospitals and clinics. In addition, the Group provides cleaning services for numerous different places such as universities, large exhibition centers, Hong Kong International Airport, housing estates and private institutions.During the Year, the Group successfully awarded a 3-year contract from the Marine Department of the Government for approximately HK$150 million for the provision of “Marine Refuse Cleansing and Disposal Services in the Eastern waters of Hong Kong”. This contract marks a significant milestone for Baguio, as it represents a strategic expansion of its service portfolio from land to sea, further strengthening its leading position in Hong Kong’s integrated environmental services market. Under the contract, Baguio delivers comprehensive marine refuse cleansing and ship refuse collection services in the Eastern waters of Hong Kong starting from 1 October 2025 including, but not limited to: Victoria Harbour, Central, Sheung Wan, Causeway Bay, Tsim Sha Tsui, Yau Ma Tei, Cheung Sha Wan, Shau Kei Wan, Kwun Tong, Sai Kung, Tolo Harbour and Tai Po. Winning this contract signifies strong market recognition of Baguio’s outstanding performance over the past 46 years. The Group will seamlessly extend its professional standards and operational efficiency in land-based waste management to the marine environment, striving to safeguard Hong Kong’s valuable marine ecosystem and present a cleaner, more beautiful Victoria Harbour to both residents and tourists.Waste management and recycling business recorded revenue of approximately HK$277.8 million, accounting for approximately 11.5% of the Group’s total revenue. The gross profit margin of the waste management and recycling business increased from 11.6% for the same period last year to 15.0%, driving the gross profit of this business up by approximately 25.2% to approximately HK$41.9 million, mainly due to the Government’s proactive promotion of recycling and the substantial expansion of the network of recycling spots, including those for food waste, which facilitated public participation and effectively stimulated collection, and the contribution from the green technology business.The Group continued to provide Government-related waste collection services to five districts, serving a population of approximately 1.6 million.In terms of recycling, the Group is contracted by the Environmental Protection Department (“EPD”) of the Government to provide collection services for thousands of recycling spots (including plastics, glass bottles, metals, waste paper and food waste) across Hong Kong. During the Year, the Group provided collection services for recycling bins in public places and schools. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, recycling stores and smart recycling machines, and other institutions in Hong Kong. In addition, Baguio also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong, and is one of the market leaders. In addition, during the Year, the Group was successfully awarded two 35-month contracts from the EPD, with a total value of approximately HK$43 million. During the Year, the Group was responsible for operating the “GREEN@Tai Wo” and “GREEN@Po Lam” recycling stores, and collaborated with nearby buildings, organizations, and community stakeholders to establish and operate fixed and mobile recycling spots for waste collection, provide community recycling support to facilitate citizens, and promote and educate the public on waste sorting and recycling in the community to strengthen citizens’ recycling habits.As a leading environmental services provider in Hong Kong, the Group provides integrated environmental management solutions including waste management, smart recycling and professional landscaping services to Kai Tak Sports Park, which hosts major sports events and concerts. With excellent environmental protection technologies and experience in operating large-scale international venues, the Group has fully demonstrated its strength in undertaking large-scale international programmes and delivering high-quality services. During the Year, the Group also provided waste recycling services for various Lunar New Year fairs across Hong Kong Island, Kowloon and the New Territories.Regarding green technology business, the Group won a new contract in relation to the development and supply of a new generation of solar-powered compacting refuse bins to the Government. This innovative product is designed with an auto-sensing inlet and indicator lights, and under its sealed design, it is equipped with devices for ventilation, lighting, and deodorization. Meanwhile, it is equipped with a big data platform and wireless technology to monitor data in real time, enabling effective tracking of the status of waste collection points, strategic deployment of resources, optimization of operational efficiency, and enhanced planning for future initiatives. Furthermore, the solar-powered compacting refuse bins adopt solar panels and rely on renewable energy, which significantly reduces carbon emissions. They can be flexibly deployed in various scenarios, suitable for remote areas where there are no refuse collection points. This product is expected to be gradually launched into the market in 2026.The Group seizes the opportunity of smart city development and has been committed to expanding its market share of smart recycling in recent years. Currently, Baguio’s smart recycling products, such as smart recycling machines, smart food waste recycling machines, and smart balances, have been deployed in different places across Hong Kong, including Government venues and schools, private housing estates, commercial buildings, theme parks, large-scale exhibition venues, and sports stadiums. These products provide the public with convenient recycling services 24 hours a day and help increase Hong Kong’s overall recycling volume.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun converts yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.As for the landscaping business, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, Hong Kong Housing Authority, Hospital Authority, Hong Kong Jockey Club, Hong Kong Science Park, the University of Hong Kong, Hong Kong University of Science and Technology, Hong Kong Wetland Park, as well as 33 sports turf venues under the Leisure and Cultural Services Department, etc. During the Year, the Group provided landscaping services for Kai Tak Sports Park, Hong Kong International Airport, Hong Kong-Shenzhen Innovation and Technology Park, Nano Parks, the Tung Chung New Town Extension (West), Hung Shui Kiu/Ha Tsuen New Development Area and the ventilation building at the eastern portal of the Tseung Kwan O – Lam Tin Tunnel.For pest management business, the Group provided pest management services for venues in the Tsuen Wan District during the Year. In addition, the Group provided pest and rodent control services for hospitals, clinics and the headquarters of the Kowloon East, Kowloon Central and Kowloon West Clusters under the Hospital Authority. The Group also continued to provide termite control and monitoring services for 24 temples under the Chinese Temples Committee.The Promotion of Recycling and Proper Disposal of Products (Miscellaneous Amendments) Bill 2025 submitted by the Government was passed by the Legislative Council during the Year. This bill establishes a common legal framework for producer responsibility scheme applicable to different products. Under this framework, the Government plans to submit the producer responsibility scheme on plastic beverage containers and beverage cartons in 2026. The scheme encourages citizens to return used containers for recycling to earn rebate, which will help significantly increase the recycling rate. Benefiting from the scheme, Baguio’s recycling volume is expected to be directly driven up, providing attractive returns for the Group’s long-term investments in recycling services and competitive barriers.The Government is actively developing the Northern Metropolis. Four new development areas include Kwu Tung North/ Fanling North, Hung Shui Kiu/Ha Tsuen, Yuen Long South, and San Tin Technopole are under construction. The Government has resumed more than 400 hectares of private land within these four new development areas, completed land levelling for 80 hectares, and is progressively handing over these lands to relevant departments for building road and railway infrastructure, public and private housing, schools, public markets, ecological conservation, as well as development of innovation and technology industry. The Group believes that this will bring opportunities for many of its core businesses.Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2025 annual results announcement, please visit the following website: https://www.baguio.com.hk/en/investor/notices/About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental management solution providers. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, green products, horticulture & landscaping, and pest control. The Group delivers innovative environmental solutions using the latest technologies to serve a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city for a greener tomorrow. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 今日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK）作為聯席保薦人、保薦人兼整體協調人、聯席全球協調人、聯席帳簿管理人及聯席牽頭經辦人，成功助力浙江凱樂士科技集團股份有限公司（「凱樂士科技」，股份代號：2729. HK）在香港聯交所主板上市，充分彰顯國泰海通集團在跨境資本運作、高效整合資源、服務專精特新科技企業方面的綜合實力。（國泰君安國際投行團隊出席上市儀式）作為綜合智能場內物流機器人龍頭企業，凱樂士科技業務橫跨29個不同行業及境內外19個國家及地區，兩次獲得國家工業和信息化部授予的國家級專精特新「小巨人」企業認證。本次發行最終定價為每股16.66港元，總發售股數達3,679.80萬股，發行規模6.13億港元。國際配售和香港公開發售錄得踴躍認購，國際配售認購倍數達3.37倍，香港公開發售認購倍數達2153.26倍，充分展現了國際資本對中國高端製造的堅定信心，也生動展示了國泰海通服務科技創新與產業升級的成果。凱樂士科技的成功上市，是繼龍旗科技（股票代碼：9611.HK）、愛芯元智（股票代碼：0600.HK）後，國泰君安國際在今年完成的第三個科技創新領域保薦項目，彰顯了國泰君安國際作為一流投行的綜合實力與卓越執行力。依託與總部國泰海通的協同優勢，公司不僅展現出在複雜跨境資本運作中高效整合資源、精准把握市場視窗的專業能力，更憑藉對「專精特新」及高端製造領域的深刻洞察，持續為中國科技企業走向國際資本市場搭建堅實橋樑。展望未來，國泰君安國際將繼續秉持金融服務實體經濟的初心，以更高水準的綜合金融服務，助力更多中國優質企業揚帆遠航，在全球資本市場書寫新的篇章。關於凱樂士科技凱樂士科技是領先綜合智能場內物流機器人提供商，擁有廣泛的機器人技術能力及多元化的自主研發機器人產品組合，涵蓋廣泛採用的高度和有效載荷規格的核心場內物流功能。凱樂士科技在極窄巷道自主移動機器人及四向穿梭車等主要類別的尖端智能場內物流機器人的出貨量處於領先地位。凱樂士業務橫跨29個不同行業及境內外19個國家及地區，並且成功交付實施了超過1,600個項目，其下游客戶涵蓋各行各業的領先企業，包括醫藥、3C電子產品、新能源及汽車行業的領先企業。憑藉立足中國，全球領先的長期戰略，凱樂士科技將持續受益於中國企業出海的浪潮，成為中國企業出海的關鍵場內物流基礎設施推動者。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港為業務基地，並在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，為客戶境外資產配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）為中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - USPA Global 的娛樂子公司 Global Polo 延續與 ESPN 的歷史性合作關係，持續推廣馬球運動，其影響力已擴及全球數百萬家庭。這項里程碑式的合作包含：傳奇ESPN解說員克里斯·福勒將首度主持3月29日的USPA金盃®決賽，並於4月26日第二度主持美國公開馬球錦標賽®決賽。賽事將於佛羅里達州棕櫚灘縣的USPA國家馬球中心舉行，屆時他將與資深播報員肯尼·萊斯及馬球名人堂成員亞當·斯諾共同主持。Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco「我有幸報導過體育界許多最具標誌性的賽事，而讓我持續被馬球運動吸引的，正是馬球選手與馬匹之間獨特的夥伴關係，以及頂級賽事中那令人屏息的速度與激烈程度，」福勒表示。「能同時主持美國馬球協會金盃賽與美國公開馬球錦標賽，讓我得以將這項美麗運動的活力與獨特性，分享給更廣大的ESPN觀眾。」「親眼見證這些世界級運動員與他們的馬匹夥伴，在如此節奏明快且講求策略的比賽中競技，是無與倫比的體驗，」福勒補充道。美國馬球協會金盃（USPA Gold Cup）始於1974年，是美國馬球界僅次於美國公開馬球錦標賽（U.S. Open Polo Championship）的第二大賽事，而後者則始於1904年。今年的賽事將於3月4日至29日舉行，屆時將有10支頂尖隊伍在最高水平的競技中一較高下。而備受矚目的美國公開馬球錦標賽將於4月1日至26日舉行，該賽事被公認為眾多世界頂尖球員與馬匹的展示舞台，至今仍是全球最具聲望的馬球賽事之一。自2004年移師佛羅里達州棕櫚灘郡以來，這兩項賽事便一直接連舉行。這些備受矚目的馬球賽事將於佛羅里達州威靈頓的美國馬球協會國家馬球中心（NPC）內，美國馬球協會第一球場舉行。四月初的美國馬球協會金盃（USPA Gold Cup）決賽，以及隨後於五月舉行的美國公開馬球錦標賽（U.S. Open Polo Championship）決賽，都將透過ESPN2等多個ESPN平台進行轉播。具體播出時間請查閱當地節目表。「我們與ESPN的長期合作關係，持續提升馬球運動、U.S. Polo Assn.品牌及其背後的全球影響力，」USPA Global總裁兼執行長J. Michael Prince表示。該公司負責管理市值數十億美元的全球運動品牌U.S. Polo Assn. 「克里斯·福勒（Chris Fowler）的回歸，以及他將同時主持USPA金盃賽與美國公開馬球錦標賽的擴展參與，進一步強化了這些世界級賽事在全球觀眾心中的熱度與能見度。」「在ESPN的支持下，馬球運動持續吸引著全球球迷的關注，」普林斯補充道。除了現場賽事轉播外，ESPN 平台還將播出由 Global Polo 製作、兩度獲獎的節目《Breakaway：U.S. Polo Assn. 呈獻》的新集數。觀眾可透過 Global Polo 的 YouTube 頻道收看獨家幕後花絮、球員專訪及錦標賽精華片段，其中包含與 USPA 金盃賽及美國公開馬球錦標賽轉播相關的特別報導。「美國馬球協會（USPA）很高興看到這項運動透過與ESPN的合作關係持續發展，」美國馬球協會（USPA）主席史都華·阿姆斯壯表示。「USPA金盃賽與美國公開馬球錦標賽代表著美國賽季中，在USPA國家馬球中心舉行的最高水準賽事，而ESPN所提供的更高曝光度，更凸顯了定義我們這項運動的運動精神、奉獻精神與傳統。」欲獲取最新資訊與即時快訊，請至 globalpolo.com 訂閱《Polo Insider》電子報，並造訪 uspolo.org。關於 ESPNESPN 作為全球領先的多平台體育娛樂品牌，旗下擁有七個美國電視頻道、頂尖的體育應用程式、直接面向消費者的 ESPN+ 服務、領先的社交與數位平台、ESPN.com、ESPN Audio，以及遍及全球各大洲的業務據點等。關於 U.S. Polo Assn. 與 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌。USPA 成立於 1890 年，是美國規模最大的馬球俱樂部與馬球選手組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 實體門市及數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 為全球 190 多個國家的男女及兒童提供服飾、配件與鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以欣賞這項令人振奮的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽和一級方程式賽車並列為全球頂尖的運動授權商之一。此外，這個受運動啟發的品牌因全球業務拓展及體育內容而屢獲國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。關於美國馬球協會® (USPA)美國馬球協會® 的成立宗旨在於推廣馬球運動；協調其會員俱樂部及註冊球員的活動；籌辦並監督馬球錦標賽、競賽及比賽；並為相關賽事制定規則、讓分制度及賽事條件。其核心目標在於提升這項運動的水平，並促進人類與馬匹參與者的安全與福祉。USPA 成立於 1890 年，是北美地區規模最大的馬球自願性體育組織。USPA 目前擁有超過 200 家會員俱樂部及 5,000 多名註冊球員會員。該協會每年頒發獎項並監督由其會員俱樂部主辦的約 50 場全國性錦標賽。如需更多資訊，請造訪 uspolo.org。如需更多資訊，請聯絡：香農·斯蒂爾森（Shannon Stilson）－體育行銷與媒體副總裁 電話 +001.561.227.6994 － 電子郵件：sstilson@uspagl.com史黛西·科瓦爾斯基（Stacey Kovalsky）－全球公關與傳播副總裁 電話 +001.954.673.1331 - 電子郵件：skovalsky@uspagl.com克里斯汀·卡爾卡尼奧（Christine Calcagno） - ESPN 傳播部資深公關專員 電話 +001.959.216.8036 - 電子郵件：christine.b.calcagno@espn.com消息來源：USPA Global Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Global Polo, the entertainment subsidiary of USPA Global, continues its historic relationship with ESPN to showcase the sport of polo, which has expanded its reach to millions of households worldwide. The landmark relationship includes legendary ESPN commentator Chris Fowler hosting the USPA Gold Cup® Final on Mar. 29 for the first time, and the U.S. Open Polo Championship® Final on Apr. 26 for the second year, at the USPA National Polo Center in Palm Beach County, Florida, alongside veteran broadcasters Kenny Rice and Polo Hall-of-Famer Adam Snow.Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco"I've had the privilege of covering some of the most iconic events in sports, and what continues to draw me back to the sport of polo is the unique partnership between the polo player and polo pony, as well as the speed and intensity of competition at the highest level," said Fowler. "Hosting both the USPA Gold Cup and the U.S. Open Polo Championship allows me to share the energy and uniqueness of this beautiful sport with a broader ESPN audience.""There's nothing quite like seeing these world-class athletes and their equine partners compete in such a fast-paced, strategic game," Fowler added.The USPA Gold Cup, first played in 1974, is the second most important tournament in American polo, right next to the U.S. Open Polo Championship, which was first played in 1904. This year's competition will feature 10 elite teams competing at the highest level of the sport from March 4 - 29. The prestigious U.S. Open Polo Championship, played April 1 - 26, is widely recognized as a showcase for many of the world's top players and equine athletes and remains one of the most prestigious polo tournaments globally. Both tournaments have been played back-to-back since they arrived in Palm Beach County, Florida, in 2004. These highly rated polo competitions take place on the U.S. Polo Assn. Stadium Field One at the USPA National Polo Center (NPC) in Wellington, Florida.Coverage of the USPA Gold Cup final in early April, followed by the U.S. Open Polo Championship final match in May, will be available on multiple ESPN platforms, including ESPN2. Check your local listings for specific airtimes."Our long-term relationship with ESPN continues to elevate the sport of polo, the U.S. Polo Assn. brand, and the global momentum behind it," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar global sport brand, U.S. Polo Assn. "Chris Fowler's return and expanded presence hosting both the USPA Gold Cup and the U.S. Open Polo Championship further strengthens the momentum and visibility of these world-class tournaments to a global audience.""Supported by ESPN, the sport of polo continues to garner interest from fans around the world," added Prince.Beyond live game coverage, ESPN platforms also feature new episodes of the two-time award-winning show, Breakaway: Presented by U.S. Polo Assn. produced by Global Polo. Viewers can follow exclusive behind-the-scenes coverage, player features, and championship highlights on Global Polo's YouTube channel, including special coverage tied to the USPA Gold Cup and the U.S. Open Polo Championship broadcasts."The United States Polo Association is delighted to see the continued growth of the sport through our relationship with ESPN," said Stewart Armstrong, Chairman of the United States Polo Association (USPA). "The USPA Gold Cup and the U.S. Open Polo Championship represent the highest level of competition at the USPA National Polo Center for the American season, and the increased visibility provided by ESPN underscores the athleticism, dedication, and tradition that define our sport."For the most up-to-date information and breaking news, sign up for the Polo Insider newsletter at globalpolo.com and visit uspolo.org.About ESPNESPN, the world's leading multiplatform sports entertainment brand, features seven U.S. television networks, the leading sports app, direct-to-consumer ESPN+, leading social and digital platforms, ESPN.com, ESPN Audio, endeavors on every continent around the world, and more.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the United States Polo Association® (USPA)The United States Polo Association® is organized and exists for the purposes of promoting the game of polo; coordinating the activities of its member clubs and registered player members; arranging and supervising polo tournaments, competitions, and games; and providing rules, handicaps, and tournament conditions for those events. Its overarching goals are improving the sport and promoting the safety and welfare of its human and equine participants. Founded in 1890, the USPA is the largest voluntary sports organization in North America for the sport of polo. The USPA is currently made up of more than 200 member clubs and over 5,000 registered player members. It annually awards and oversees roughly 50 national tournaments hosted by its member clubs. For more information, please visit uspolo.org.For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.954.673.1331 - E-mail: skovalsky@uspagl.comChristine Calcagno - Sr. Publicist, ESPN CommunicationsPhone +001.959.216.8036 - E-mail: christine.b.calcagno@espn.comSOURCE: USPA Global Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國抗體製藥有限公司（「中國抗體」或「公司」，連同旗下附屬公司統稱「集團」，股份代號：03681.HK）欣然公布截至2025年12月31日止年度（「年內」）的全年業績。年內，公司虧損由截至2024年12月31日止年度的人民幣1.85億元减少人民幣0.80億元至約人民幣1.05億元，主要得益于公司聚焦SM17 1b期臨床、劑型橋接研究及2期臨床籌備，研發成本較2024年大規模臨床研究有所下降。截至2025年12月31日，公司可動用資金總額約人民幣3.52億元，較上年同期的人民幣1.41億元顯著增長。年內，集團獲得睿遠、富國、易方達等多家知名機構投資者支持，公司完成兩輪股份配售，合計募集所得款項淨額約4.93億港元，帶動融資活動所得現金流淨額達人民幣3.29億元，爲後續研發及臨床推進提供了充足資金支持。核心産品SM17取得多項突破性進展SM17是全球首創（First-in-Class）的靶向IL-25受體的人源化單抗，通過靶向II型免疫核心「警戒素（Alarmin）」分子白細胞介素25（IL-25）受體，調節II型炎症反應。SM17具有治療特應性皮炎（AD）、炎症性腸病（IBD）、哮喘、慢性鼻竇炎伴鼻息肉（CRSwNP）及特發性肺纖維化（IPF）的潜力。在特應性皮炎（AD）領域，SM17精准作用于II型免疫反應的上游，通過阻斷被稱作「警報素「的關鍵細胞因子IL-25，從源頭上抑制導致AD的炎症級聯反應。當前，已獲批上市的AD療法（包括生物製劑）雖然可以大大改善患者的濕疹面積和嚴重程度指數以及生活質量。然而目前在研在售藥物無法同時滿足快速起效止癢，皮損恢復，同時具備良好安全性的臨床需求，市場尚存在巨大空間。SM17的創新之處在于，它通過靶向Th2炎性細胞因子通路上游（如IL-25受體），從而對下游信號通路的致病因子産生抑制效果，且在臨床前研究中展現出快速止癢、顯著修復皮損以及良好安全性的潜力，直擊現有療法痛點。2025年4月，SM17在中國治療中重度特應性皮炎的1b期研究中，取得了令人鼓舞的積極結果：揭盲後的12周頂線數據顯示，高劑量組的91.7%的患者實現瘙癢緩解指標（NRS-4），75%達到皮損恢復(EASI75)指標，41.7%達到完全或近乎完全清除AD症狀指標（IGA 0/1）。該結果顯著優于IL4/IL-13類單抗藥物且安全性與耐受性顯著優于Janus激酶抑制劑（JAK抑制劑），這使得SM17有望成爲一款可同時實現快速止癢、皮膚損傷修復，且安全性表現優异的同類首創及同類最優療法。SM17的研究成果已在多家國際頂級期刊發表。預計最早在2026年年中進入AD的2期臨床試驗。此外，SM17持續拓展出多個新的適應症，于本年度第二季度，SM17的適應症拓展進一步取得突破性進展。2025年12月11日，SM17用于治療IBD的新藥研究申請（「IND」）已提交予中國國家藥品監督管理局（「中國國家藥監局」）藥品審評中心（「藥品審評中心」），幷已獲受理，且IND隨後于2026年2月獲批。此次IND的提交，代表著SM17治療範圍從AD拓展至IBD的重要里程碑，涵蓋克羅恩病（「CD」）及潰瘍性結腸炎（「UC」）等慢性、衰竭性疾病，這些疾病存在顯著未滿足的醫療需求。于2025年10月，首組健康受試者已在中國給藥途徑轉換之1期橋接臨床研究中給藥。截至2025年12月31日，合共三十名健康受試者已入組且對全部健康受試者之隨訪于2026年2月完成。該橋接研究預期于2026年第二季度前完成。該研究數據將用作支持IBD適應症的進展直接推進2期臨床開發。早期在研管線布局提供持續創新動力在早期在研管線方面，公司持續取得積極進展。2025年6月合作夥伴雲頂新耀公布了EVER001（中國抗體SN1011）用于治療原發性膜性腎病（PMN）的1b/2a期臨床試驗的積極結果，進一步提升了管線的商業化價值。同時，公司多項早期研發項目穩步推進。其中，抗CGC抗體是一款內部開發的全球首創人源化抗γc抗體。動物研究顯示，該抗體可能透過調節免疫細胞的擴增、自身反應性及組織浸潤，成爲治療白癜風、斑禿，甚至其他自身免疫性疾病的潜在治療藥物。目前正在針對該抗體進行CMC優化及毒理學研究，幷計劃最早在2026年第四季度前提交其治療斑禿的IND申請。雙特异性抗體候選藥物是一種新型雙特异性抗體，靶向核因子kappa-B配體受體激活因子(RANKL)及骨硬化蛋白，治療骨相關適應症。通過的內部體外及體內研究顯示，相較于市售批准的抗體（如地諾單抗及羅莫珠單抗），該候選藥物展現出更佳的療效。目前正在進行CMC優化，幷在非人靈長類動物中測試其毒性，幷計劃最早在2027年上半年前提交IND申請。協同推進戰略合作與BD授權，榮獲多項重磅榮譽公司于2025年8月與中山大學香港高等研究院有限公司（「SYSU-IAS」）簽訂全面戰略合作協議，本公司可直接使用SYSUIAS完備的實驗室設施與寶貴的數據資源，幷獲得包括靈長類及非靈長類實驗動物在內的科研資源支持，加速創新藥物研發進程，推動科研成果在全球範圍內向臨床應用轉化。同時公司正積極探索運用人工智能(AI)技術開展新靶點發現的可行性。2026年1月，公司受邀參加摩根大通醫療健康大會（JPM大會）幷與多家MNC、投資者分享了公司在自免領域的進展。依托雄厚的研發實力、豐富的管線儲備及精細化運營管理，公司于本年度榮獲多項重磅榮譽，包括粵港澳大灣區家族辦公室協會與香港國際家族辦公室協會聯合頒發的第二届「新質生産力企業大獎」，以及智通財經授予的「最具價值醫藥公司獎」。中國抗體董事長、執行董事兼首席執行官梁瑞安博士表示：「2025年，我們憑藉扎實的臨床數據證明了創新管線的全球競爭力，SM17在AD中的優异表現及其向IBD的拓展，標志著我們正從單一産品研發邁向平臺價值的持續兌現。展望2026年，生物醫藥行業正加速邁入『生物技術3.0時代』，創新驅動、多學科融合及全産業鏈智能化將成爲核心發展方向。我們將把握中國生物醫藥對外授權高速增長的歷史機遇，持續推進核心管線的臨床開發，深化國際合作布局。依托堅實的現金儲備、完善的産業鏈能力以及差异化創新優勢，爲股東創造長期價值，幷爲患者提供具有突破性的治療方案。」關于中國抗體製藥有限公司中國抗體製藥有限公司（股份代號：03681.HK）是首創新藥及潜在同類最佳抗體藥物研發領域的開拓者，專注于自身免疫性疾病、以及由此導致的神經系統疾病及其他難治的耗損性疾病，致力于解决未被滿足的醫療需求。中國抗體始終致力于開發針對全新靶點及通過創新機制的治療性抗體，旨在現有療法效果不佳的領域實現差异化臨床成果。其豐富的研發管線包括：SM17在AD治療中展現出卓越的止癢效果、皮膚清除率及安全性，同時在哮喘和特發性肺纖維化（IPF）領域具有應用潜力；其旗艦抗CD22舒西利單抗，除了臨床驗證對類風濕關節炎（RA）具有臨床療效外，目前正針對系統性紅斑狼瘡（SLE）和阿爾茨海默病開展臨床評估；另一款抗CGC（共同γ鏈）創新單抗，正準備進入治療斑禿和白癜風的臨床研究；中國抗體亦研發了一款能同時刺激骨胳生長及抑制骨胳流失、治療骨質疏鬆症的雙特异性抗體。中國抗體以突破性療效爲核心追求，不斷重新定義患者護理標準，穩居突破性療法領域的領軍地位。此新聞稿由真灼財經代中國抗體製藥有限公司發布投資者及媒體查詢聯絡人：Bunny LeeCitrus JiangWendy Huang電話：（852）5316 9995電郵：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 這家承載356年品牌傳承的中醫醫療服務龍頭近日正在港股招股，背靠"老字號"，補齊了同仁堂集團"制藥-零售-醫養"大健康生態圈的最後一塊拼圖 。本次全球發售1.08億股，其中香港公開發售約10%，國際發售約90%。基石投資者已鎖定占發行規模逾46%，基石占比接近最高限額。機構真金白銀入場：基石比例高，機構參與熱度足數據是最誠實的信號。據招股書披露，基石投資者航空港科技資本（香港）及Aurora SF將按發售價認購總金額約3.89億港元的股份，占全球發售規模逾46%，這一比例在近期港股IPO中處於較高水平。基石鎖定比例高意味著上市後可流通籌碼有限，對二級市場價格支撐更強。此外，基石鎖定期超過傳統規定的6個月，進一步增強了市場的預期。獲客成本極低：僅為同行業的六十分之一在醫療服務行業，獲客成本是決定盈利天花板的關鍵變量。同仁堂醫養背靠始創於1669年的"同仁堂"金字招牌，品牌壁壘的經濟價值可以用一個數字概括：2024年推廣費占收入比例僅約0.2%。然而就診人次卻從2022年的132.1萬飆升至2024年的297.7萬，CAGR高達50.1%。2025年前9月達253.6萬，同比再增21.5%。會員從43.6萬增至76.7萬（2025年9月），複購粘性強勁。隨著收入規模擴大，同行需要花在營銷上的每一分錢，對同仁堂醫養而言幾乎都可以直接轉化為利潤。這是任何競爭對手都無法在短期內複制的護城河。盈利拐點已確立：經調整淨利潤增長29%對於處於上市窗口的成長型企業，投資者最關心的是：盈利趨勢是向上還是向下？答案很明確——向上，且加速。財務數據顯示，公司已展現出穩健的盈利能力。2022年至2024年，公司已由虧損923萬元轉為盈利4620萬元，經調整淨利潤達6173萬元，增長達到29%；毛利同期從1.43億元增至2.22億元，年複合增長率為 24.8%；2024年現金轉化率87.2%，有息債務占比僅11.56%，持有現金2.25億元，盈利質量顯著提升 。同仁堂醫養當前的發展階段與固生堂上市時高度相似，盈利能力剛進入釋放通道，增長最快的階段可能尚未到來。複制增長階段：計劃新增20家醫療機構中醫醫療服務是業績基本盤，公司已構建包含25家醫療機構的分級診療網絡，其中自有醫療機構12家，管理醫療機構12家，此外還有1家互聯網醫院提供線上診療服務。截至2024年就診人數約300萬人，CAGR高達50.12%；2025年前9月約253.6萬，同比再增21.5%；會員數量約74萬人，合作藥店約500餘家。作為同仁堂集團打開增長空間的核心業務，醫療服務板塊規模還需要更強力的支持與擴張。根據其募集資金使用披露，該公司計劃新收購5家醫療機構、以輕資產的方式新建5家醫療機構，並額外向5-10家醫療機構提供管理服務。可見，其未來快速擴張的戰略清晰，"收購+輕資產新建+管理輸出"三路徑協同。非"名醫驅動"：依靠標准化"體系驅動"對中醫醫療服務企業而言，最大的成長瓶頸在於"名醫能否複制"。同仁堂醫養正在用一套體系化的方法論回答這個問題。公司向上遊延伸，自建了供應鏈體系，完成了端到端的產業鏈閉環。除藥品外，健康產品銷售也實現了品牌價值的商業化變現。公司已獲授權在浙江省獨家銷售同仁堂爆款安宮牛黃丸系列產品，截至最後實際可行日期，公司已向超過4000家機構客戶銷售健康產品及其他產品。此外，公司將雲數字化系統紮根進網絡內每一家醫療機構，通過實時數據分析及管理，用智能系統代替"院長"，正在向"人機協作式"新型連鎖醫療管理方式過渡。讓增長不再完全依賴於個別名醫的"人治"，而是依托可複制的運營體系、數字化中臺和人才培養機制，實現規模化、標准化擴張。AI+中醫：醫藥數據壁壘深厚作為同仁堂集團在中醫服務領域唯一戰略性布局的載體，同仁堂醫養正站在傳統中醫與人工智能交匯的曆史拐點上 。同仁堂集團近期積極推動AI技術在中醫藥領域的落地應用，已與小米聯合打造"AI智能中醫藥健康服務智能體"，將傳統中醫智慧與現代AI技術深度融合，形成"咨詢—建議—服務—購藥"的服務閉環 。展望未來，萬億規模的中醫醫療服務市場正迎來龍頭整合的黃金窗口期。同仁堂醫養以多輪驅動的發展模式、穩健的財務基礎及AI技術的前瞻布局，不僅完成了老字號資本版圖的最後一塊"拼圖"，更開啟了中醫服務與前沿科技深度融合的新紀元。隨著上市募集資金的到位，相信同仁堂醫養有望加速推進核心業務的全面AI轉型，在萬億級中醫醫療服務市場中持續鞏固龍頭地位，引領行業邁向智能化新時代。轉載自格隆匯 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國領先的技術驅動移動出行平台嘀嗒出行（「嘀嗒」或「公司」，股票代碼：02559.HK）公佈了截至2025年12月31日止年度的經審計綜合年度業績。財務亮點：-截至2025年12月31日止年度，收入為人民幣5.02億元，2024年同期為7.87億元。-截至2025年12月31日止年度，毛利為人民幣3.33億元，2024年同期為5.67億元。-截至2025年12月31日止年度，淨利潤為人民幣1.30億元，2024年同期為10.04億元。-截至2025年12月31日止年度，經調整淨利潤（非國際財務報告準則計量）為人民幣1.38億元，而2024年同期為2.21億元。運營亮點：-截至2025年12月31日止年度，交易總額達人民幣47億元，訂單總數達到8090萬。-截至2025年12月31日，註冊用戶數超過4.15億。-截至2025年12月31日，認證私家車主數量達到約2100萬。業務展望：出行相關業務2025年是嘀嗒出行從專注于順風車的平台，向更為綜合的出行及車輛服務平台轉型的關鍵之年。2025年，嘀嗒出行推出了聚合打車業務，來進一步豐富平台的出行場景，使「中短途+立即出發」的即時出行需求與順風車「中長途+預約出行」的場景形成有效互補，增強用戶在不同出行決策場景下的選擇彈性。嘀嗒出行還開啟了二手車交易線索業務，拓展車輛全生命週期的業務範圍，並提升車主生態的用戶參與度。嘀嗒出行認為，順風車在中國仍處於早期發展階段，有潛在的巨大市場需求還未被充分釋放，而順風車的益處還未被完全認知。嘀嗒出行將持續致力於創新，圍繞平台的出行場景，繼續發展平台獨特的競爭優勢和價值，以更好地服務用戶群體。未來，嘀嗒出行計劃進一步發展聚合打車業務及其他出行相關服務，並持續擴展服務品類。有關嘀嗒出行截至2025年12月31日止年度全年業績公告的完整內容，請訪問：https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf關於嘀嗒出行嘀嗒出行（「嘀嗒」或「公司」，股票代碼：02559.HK）是中國領先的技術驅動型出行平台。公司通過提供順風車平台服務，為乘客和出行路線及時間相近的私家車主進行匹配，從而在不增加環境負擔的前提下創造了更多運力。公司還提供聚合打車服務，以滿足更多元的出行場景需求。嘀嗒出行致力於讓出行生態更綠色、更高效，讓每一次出行體驗溫暖而愉悅。前瞻性聲明本新聞稿包含有關公司業務前景、預測業務計劃和增長戰略的前瞻性陳述。這些前瞻性陳述基於公司目前信息，並基於本新聞稿發佈時的前景進行陳述。它們基於某些期望、假設和前提，其中一些是主觀的或不可控的，可能被證明是不正確的，未來可能無法實現。前瞻性陳述背後存在大量風險和不確定性。有關這些風險和不確定性的更多信息，請參閱公司網站上的其他公開披露文件。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com